Novel Targeted Therapy Zidesamtinib Achieves 94% Response Rate in Pivotal Trial for ROS1-Positive Lung Cancer

For patients newly diagnosed with ROS1-positive non-small cell lung cancer, the targeted therapy zidesamtinib shrinks tumors in 94% of cases and effectively clears cancer that has spread to the brain. These pivotal trial results mean the drug is highly likely to become the new standard first-line treatment, offering a durable oral option that delays the need for intravenous chemotherapy. The data, presented at the 2026 World Conference on Lung Cancer in Seoul, South Korea, fundamentally shifts the prognosis for a specific subset of lung cancer patients. By answering the critical question of whether next-generation inhibitors should be used immediately or saved for later, the findings provide a clear mandate for frontline use.[1][5]

The findings stem from the phase 1/2 ARROS-1 clinical trial, which enrolled 94 patients who had never previously received a tyrosine kinase inhibitor. Among this frontline group, 88 patients saw their tumors shrink significantly, achieving an objective response rate of 94%. Even more remarkably, 15% of the trial participants achieved a complete response, meaning advanced imaging could no longer detect any trace of cancer in their bodies. These figures represent a substantial improvement over older targeted therapies, which typically offer lower response rates and shorter durations of disease control before the cancer inevitably mutates and resumes its growth.[3][5]

The most reassuring finding for patients is the drug's ability to cross the blood-brain barrier. ROS1-positive lung cancer has a high tendency to spread to the central nervous system, which historically complicates treatment because many older drugs cannot penetrate brain tissue effectively. In the ARROS-1 trial, all 10 patients who entered the study with measurable brain metastases responded to the therapy. Seven of those patients saw their brain tumors disappear entirely, achieving a 70% complete intracranial response rate. For patients, this means a drastically reduced risk of debilitating neurological symptoms and a lower immediate need for localized brain radiation.[1][5]

Zidesamtinib, which is marketed by GSK under the brand name Jideytro, was specifically engineered to overcome the structural limitations of first-generation ROS1 inhibitors. Older drugs in this class often trigger resistance mutations or cause severe neurological side effects by accidentally blocking a related protein called TRK. By selectively targeting only the ROS1 fusion protein and sparing TRK, zidesamtinib avoids these off-target effects. This precision allows patients to stay on the medication longer without experiencing the dizziness, weight gain, and nerve pain that frequently force patients to lower their doses or abandon older therapies entirely.[3][4]

The durability of the treatment is equally striking, providing patients with extended periods of normal life. At the 12-month mark, 90% of the patients remained progression-free, meaning their cancer had not started growing again or spread to new organs. The median progression-free survival time has not yet been reached, suggesting the benefit extends well beyond a year for the vast majority of users. Furthermore, 86% of the patients who responded to the drug were still responding after a full year of continuous daily treatment, highlighting the compound's ability to suppress the disease over the long term.[2][5]

For anyone currently navigating a lung cancer diagnosis, these results underscore the absolute necessity of comprehensive biomarker testing before starting any treatment. ROS1 fusions occur in only 1% to 2% of non-small cell lung cancers, typically appearing in younger patients who have little to no history of smoking. Without advanced genetic sequencing of the tumor tissue, this highly treatable vulnerability goes completely unnoticed. When that happens, patients are often directed toward less effective general chemotherapy or broad immunotherapy, missing the opportunity to control their disease with a single daily pill.[1][4]

Zidesamtinib is already available to a subset of the lung cancer community. The U.S. Food and Drug Administration approved the drug in July 2026 for adults with ROS1-positive lung cancer who have already been treated with an older tyrosine kinase inhibitor. Based on these new frontline results, GSK plans to submit a supplemental application later this year to expand the approval. "Today's results show a combination of high response rates and a tolerability profile that helped most patients stay on treatment," said Hesham Abdullah, GSK's Senior Vice President and Global Head of Oncology R&D, adding that the data highlights the drug's potential "to become a first-line treatment for patients with ROS1-positive NSCLC."[5]

While the 94% response rate is unprecedented in this specific patient population, clinical researchers caution that targeted therapies are not permanent cures. Cancers driven by genetic fusions eventually mutate to outsmart even the most advanced tyrosine kinase inhibitors, meaning patients will likely need to transition to other treatments, such as chemotherapy or novel combinations, in the future. However, moving a highly tolerable, brain-penetrant drug to the front of the line buys patients years of high-quality life before those secondary options are required, fundamentally changing the trajectory of their disease management.[2][4]